Divergent Peptide Presentations of HLA-A*30 Alleles Revealed by Structures With Pathogen Peptides

Human leukocyte antigen (HLA) alleles have a high degree of polymorphism, which determines their peptide-binding motifs and subsequent T-cell receptor recognition. The simplest way to understand the cross-presentation of peptides by different alleles is to classify these alleles into supertypes. A1 and A3 HLA supertypes are widely distributed in humans. However, direct structural and functional evidence for peptide presentation features of key alleles (e.g., HLA-A*30:01 and -A*30:03) are lacking. Herein, the molecular basis of peptide presentation of HLA-A*30:01 and -A*30:03 was demonstrated by crystal structure determination and thermostability measurements of complexes with T-cell epitopes from influenza virus (NP44), human immunodeficiency virus (RT313), and Mycobacterium tuberculosis (MTB). When binding to the HIV peptide, RT313, the PΩ-Lys anchoring modes of HLA-A*30:01, and -A*30:03 were similar to those of HLA-A*11:01 in the A3 supertype. However, HLA-A*30:03, but not -A*30:01, also showed binding with the HLA*01:01-favored peptide, NP44, but with a specific structural conformation. Thus, different from our previous understanding, HLA-A*30:01 and -A*30:03 have specific peptide-binding characteristics that may lead to their distinct supertype-featured binding peptide motifs. Moreover, we also found that residue 77 in the F pocket was one of the key residues for the divergent peptide presentation characteristics of HLA-A*30:01 and -A*30:03. Interchanging residue 77 between HLA-A*30:01 and HLA-A*30:03 switched their presented peptide profiles. Our results provide important recommendations for screening virus and tumor-specific peptides among the population with prevalent HLA supertypes for vaccine development and immune interventions.


INTRODUCTION
The major histocompatibility complex (MHC), also known as the human leukocyte antigen (HLA) system in humans, plays a pivotal role in activating T-cell immune responses by presenting antigen peptides on antigen-presenting cells (APCs). The residues in the peptide-binding grooves (PBGs) of HLA molecules are highly polymorphic and this determines the peptide-binding motifs and the subsequent T-cell immunity features of people with different HLA types. At the present moment, 15,586 HLA molecules have been identified (https:// www.ebi.ac.uk/ipd/imgt/hla/stats.html). The concept of HLA supertypes offers a simple and useful way to clarify the peptidebinding features of HLA molecules with cross-presented peptide reservoirs (1)(2)(3). In particular, determining the MHC-binding peptide motif is now widely accessible as an important approach of MHC I allele classification (4). Twelve HLA supertypes (A1, A1A3, A1A24, A2, A3, A24, B7, B8, B27, B44, B58, and B62) have thus far been reported, based on their binding motifs (4)(5)(6)(7)(8). Alleles of the same supertype have similar binding motifs, which is very useful for screening special peptides presented by certain MHC I molecules and would benefit subsequent T-cell recognition and vaccine development studies.
HLA-A * 30:01 and HLA-A * 30:03 differ from one another only by five amino acids, three of which are located in the PBG (14). However, the binding motifs of these two HLA alleles are quite different from each other (4). Thus far, the supertype classification of HLA-A * 30:01 and HLA-A * 30:03 is still in debate. Initially, HLA-A * 30:01 was classified as an A24 supertype based on sequence and biological data (5), but was later reclassified Abbreviations: APCs, antigen-presenting cells; CD, circular dichroism; HLA, human leukocyte antigen; MHC, major histocompatibility complex; PBG, peptidebinding grooves; RMSD, root-mean-square deviation. as an A1 supertype using clustering of specificity matrices (6). To further complicate matters, HLA-A * 30:01 was also assigned to the A3 supertype according to bioinformatic methods (15) and then later reassigned to the A3 supertype, based on HLA-A * 30:01 binding assays (16). Meanwhile, others proposed that HLA-A * 30:01 belonged to the A1A3 supertype, based on a compilation of published motifs, binding data, and analyses of shared repertoires of binding peptides (4). In the same study, HLA-A * 30:03 was reported to be an A1 supertype allele (4). Clearly, the molecular bases of peptide presentation by HLA-A * 30:01 and HLA-A * 30:03 still need to be determined in order to precisely classify these two closely related HLA alleles.
In this study, we determined the peptide presentation features of HLA-A * 30:01 and HLA-A * 30:03 through a series of structural and functional investigations. In contrast to what was previously reported, we found that HLA-A * 30:01 and HLA-A * 30:03 may have the peptide-binding features of the A3 and A1A3 supertype, respectively. Interestingly, we found that residue 77 is key for determining the different binding motifs between HLA-A * 30:01 and HLA-A * 30:03. Our results increase the understanding of HLA supertypes and pave the way for peptide screening and vaccine development based on the binding motifs of different supertypes.

Peptide Synthesis
The peptide, NP44 (CTELKLSDY) derived from the influenza virus nucleocapsid protein (residues 44-52), RT313 (AIFQSSMTK) from the HIV reverse transcriptase (residues 313-321), and MTB (QIMYNYPAM) from Mycobacterium tuberculosis protein TB10.4 were synthesized and purified to 90% by reverse-phase HPLC and mass spectrometry (SciLight Biotechnology, Beijing, China) ( Table 1). These peptides were stored in lyophilized aliquots at −80 • C after synthesis and dissolved in dimethyl sulfoxide (DMSO) before use. Other peptides used in this paper were synthesized and purified in the same way (Tables 2, 3).

Crystallization and Data Collection
The sitting-drop vapor diffusion method was used to screen high-resolution crystals at both 4 and 18 • C using Index, Crystal Screen I/II, and PEGRx I/II kits (Hampton Research, Aliso Viejo, CA, USA) (25). Briefly, we adjusted the HLA I complex concentrations to 5, 10, 15, or 20 mg/mL with the protein buffer. Then, 1 µL of protein solution was mixed with 1 µL of reservoir solution. The resulting solution was IEDB14 LGRVRDGP --  (29) and restrained refinement was performed using the Refinement of Molecular Structures (REFMAC5) program (30). The stereochemical quality of the final model was assessed with the program, REFINE, in Phenix (31). All figures were generated using PyMOL (http://www.pymol.org/).

Thermostability Measurements Using Circular Dichroism
Circular dichroism (CD) was used to evaluate the thermostability of HLA I complexes, as previously reported (32). Briefly, the complexes were diluted to 200 µg/mL in protein buffer.
The CD spectra at 218 nm were measured on a Chirascan spectrometer (Applied Photophysics, Leatherhead, UK) using a thermostatically controlled cuvette at temperature intervals of 0.2 • C and a rate of 1 • C/min between 20 and 90 • C. The proportion of denatured protein was calculated from the mean residue ellipticity (u) using a standard method: where θ N and θ U are the mean residue ellipticity values in the fully folded and fully unfolded states, respectively. The midpoint transition temperature (T m ) was calculated using data from the denaturation curves in the program Origin 8.0 (OriginLab, Northampton, MA, USA).

Sequence Logo Plot of Amino Acid Motifs
We used one of most widely used MHC peptide binding prediction tools, NetMHCpan  Figure 1). Within these residues, Ser9 is located in the B pocket while Glu114 and His116 are in the F pocket of the PBG and therefore, may influence peptide binding. In addition, sequence alignment of HLA-A * 30:01 and HLA-A * 30:03 indicates five amino acids which are different between these two alleles (i.e., R56G, Q70H, V76E, D77N, and W152R).
To further confirm the peptide-binding motifs of HLA-A * 30:01 and HLA-A * 30:03, we mutated the P -Met residue of MTB to different A1 supertype peptide motif-preferred residues (Tyr, Phe, Ile, Leu, and Val), A3 supertype binding motif residues (Arg and Lys), and small hydrophilic amino acids (Ser and Thr) ( Table 2). We found that HLA-A * 30:03 could present MTB-M9Y, MTB-M9F, MTB-M9I, MTB-M9V, and MTB-M9L peptides with A1 supertype binding motifs and could also present the MTB-M9K peptide with A3 supertype binding motifs. However, it could not present MTB-M9R ( Table 2  with defined assays, For 15 potential HLA-A * 30:01-binding peptides with aliphatic or aromatic amino acids as P residues ( Table 3). we verified the binding of the peptides with HLA-A * 30:01 using the co-refolding assay. HLA-A * 30:01 did not show any binding capacity to any of these 15 peptides. In contrast, five peptides (IEDB1, IEDB2, IEDB9, IEDB11, and IEDB15) with Leu, Ser, Ile, Val, and Tyr at P residue could help HLA-A * 30:03 renature in vitro (Supplemental Figures 4A-E). These results also support that HLA-A * 30:01 possesses more features of A3 supertype compared to HLA-A * 30:03.  Table 4). The overall structures of these four complexes showed typical MHC I conformations ( Figure 1B). The root-mean-square deviation (RMSD) of the overall structures of HLA-A * 30:01 and HLA-A * 30:03 was 0.591, which indicated that these two molecules were extremely similar. Five amino acids differed between HLA-A * 30:01 and HLA-A * 30:03 and these were mainly located at the α1α2 domains of the heavy chains and residues 70, 77, and 152 in the PBG, which may influence peptide binding ( Figure 1C). The electron densities for these three peptides were well-defined into the PBG of HLA-A * 30:01 and HLA-A * 30:03, which indicated that the conformations of these four structures were stable (Figures 1D-G).  their cross-presentation features. Firstly, the alignment of these three structures showed that there was a similar overall conformation of the presented peptide, RT313, in the PBGs (Figure 2A). Our crystallographic data showed that although the key residues at position 74, 77, 114, and 116 are different in the F pockets of HLA-A * 11:01, HLA-A * 30:01, and HLA-A * 30:03, the binding modes of the P -Lys residue of RT313 in the F pockets of these three molecules were quite similar. The NZatom of the P -Lys residue had hydrogen bonds with Asp74, through a water molecule in HLA-A * 11:01, HLA-A * 30:01, and HLA-A * 30:03 (Figures 2B-D). Meanwhile, HLA-A * 30:01 and HLA-A * 30:03 possess a His at position 116, differed from HLA-A * 11:01, which has an Asp at this position. Similar to the direct hydrogen bond between Asp116 in HLA-A * 11:01 and P -Lys in RT313 (Figure 2C), His116 in HLA-A * 30:01 and HLA-A * 30:03 could also form hydrogen bonds with the positively-charged anchor Lys (Figures 2B-D). Although residue 77 of HLA-A * 30:01 (Asp77) and HLA-A * 30:03 (Asn77) were different, the NZ-atom of P -Lys also formed direct hydrogen bonds with Asp77 in HLA-A * 11:01 and HLA-A * 30:01 and with Asn77 in HLA-A * 30:03 (Figures 2B-D).
Special A1A3 Supertype Features in the F Pocket of HLA-A * 30:03 In addition to binding peptides through P -Lys, as do other A3 supertype members such as HLA-A * 30:01 and HLA-A * 11:01, HLA-A * 30:03 could also bind peptides with hydrophobic residues as P anchors. The P residues of MTB (Met) and NP44 (Tyr) could also form stable hydrogen bonds with the residues in the F pocket of HLA-A * 30:03 (Figures 3A,B). Furthermore, in the structure of HLA-A * 30:03/NP44, additional water molecules can help the P -Tyr of peptide NP44 bind to Asp74 and Asn77 in an α helix, to enable stable peptide binding (Figure 3B), quite similar as in the structure of HLA-A * 01:01/ NP44 (Figure 3C).
We compared the charge of the F pocket of HLA-A * 30:01 and HLA-A * 30:03 with the charge of the F pocket of the typical A3 supertype molecules, HLA-A * 03:01, HLA-A * 68:01, and HLA-A * 11:01, and the typical A1 supertype molecule HLA-A * 01:01 (Figures 3D-I). In HLA-A * 03:01, HLA-A * 68:01, and HLA-A * 11:01, residues 74, 77, and 116 were the negatively charged acidic amino acid, Asp, which resulted in F pockets with a strong negative charge (Figures 3D-F). In HLA-A * 30:01, even though residue 116 was His, not Asp, the F pocket still had strong negative charge (Figure 3G), thereby allowing HLA-A * 30:01 to bind positively charged amino acids, such as Lys and Arg. This also suggested that, when His/Asp116 is the only difference between HLA-A * 30:01 and HLA-A * 30:03, the residue in this position has little impact on the charge of the F pocket. In contrast, residue 77 was different between HLA-A * 01:01 (Asn77) and the A3 supertype alleles (Asp77). Asn has a weaker negative charge than Asp and therefore, the HLA-A * 01:01 F pocket has a weaker negative charge than the A3 supertype F pockets ( Figure 3I). The difference in the charge of the F pockets between the A1 and A3 supertypes was one of the main reasons for their different binding motifs. This suggests that residue 77 plays a key role in the definition of different supertypes.
Although residue 77 in HLA-A * 30:03 was also Asn, its F pocket was able to bind amino acids belonging to both A1 and A3 supertypes. Comparing the charge of the F pocket between HLA-A * 30:03 and HLA-A * 01:01, we found that the "mouth" of the HLA-A * 01:01 F pocket had a stronger positive charge than that of the HLA-A * 30:03 F pocket (Figures 3H,I).
Upon further analysis, we found that Arg114 of HLA-A * 01:01 pointed to the "mouth" of the F pocket to form a strong positively charged environment thereby preventing positively charged amino acids, such as Lys and Arg, from inserting into the F pocket ( Figure 3I, Supplemental Figure 5A). However, in HLA-A * 30:03, Glu114 did not form the F pocket because its side chain is much smaller than that of Arg (Supplemental Figure 5B). The strength of the negative charge of the HLA-A * 30:03 F pocket was between that of the A3 supertype and A1 supertype alleles (Figure 3H). This allowed the F pocket of HLA-A * 30:03 to accommodate both the basic amino acids preferred by the A3 supertype and the aromatic and large hydrophobic amino acids preferred by the A1 supertype.
Polymorphic Residues Distinguish the Peptide Presentation of HLA-A * 30:03 From HLA-A * 01:01 in the A1 Supertype All of the 18 amino acid polymorphisms between HLA-A * 30:03 and HLA-A * 01:01 were located at the α1 and α2 domains ( Figure 4A). Furthermore, most of these polymorphic residues were located at the PBG, which may contribute to their subtly different peptide presentations and the HLA-restriction of TCRrecognition. Among the polymorphic residues between HLA-A  Figure 4A) (35)(36)(37).
Alignment analysis of NP44 presented by HLA-A * 01:01 and HLA-A * 30:03 showed a similar overall conformation of the presented peptides in the PBGs of the two alleles ( Figure 4B). However, the side chain of P3-Glu, P5-Lys, and P7-Ser point to different orientations in HLA-A * 01:01/NP44 and HLA-A * 30:03/NP44, respectively ( Figure 4B). Further analysis revealed that Arg152 of HLA-A * 30:03 formed a salt bridge with P3-Glu. However, in HLA-A * 01:01, Arg156 also formed a salt bridge with P3-Glu, which resulted in a subtle difference in the conformation of P3-Glu ( Figure 4C). In addition, Arg156 of HLA-A * 01:01 could also form a hydrogen bond with P7-Ser. However, no hydrogen bond was seen between Leu156 and P7-Ser in HLA-A * 30:03 ( Figure 4D). Even though the P -Tyr side chain of NP44 could form a hydrogen bond with both the positively charged His116 in HLA-A * 30:03 and the negatively charged Asp116 in HLA-A * 01:01, the hydrogen bond networks of residue 114, 116, and the P -Tyr of NP44 were different ( Figure 4E). In HLA-A * 30:03, the negatively charged Glu114 could form a salt bridge with the positively charged His116 and Arg152. For HLA-A * 01:01/NP44, residue 114 was a positively charge Arg, which formed a salt bridge with Asp116 to stabilize its conformation. Ala152 is a small amino acid which was unable to form a direct contact with Arg114.

The Key Contribution of Residue 77 to the Peptide-Binding Motifs of HLA Supertypes
In order to confirm that residue 77 was the key position to determine the different binding motifs between HLA-A * 30:01 and HLA-A * 30:03, we mutated Asp77 to Asn77 in HLA-A * 30:01 (mutant, mutated HLA-A * 30:01D77N) and Asn77 to Asp 77 in HLA-A * 30:03 (mutant, mutated HLA-A * 30:03N77D). As in the binding assays, peptide RT313 could be presented by both mutated HLA molecules ( Figure 5A). However, in comparison to wild type HLA-A * 30:01, the binding capacity of HLA-A * 30:01D77N to RT313 decreased. In contrast, the binding capacity of HLA-A * 30:03N77D to RT313 increased in comparison to wild type HLA-A * 30:03 ( Figure 5B). Peptide MTB, which has an A1 supertype-binding peptide-featured P anchor, could not bind HLA-A * 30:01, but after the introduction of the D77N mutation, HLA-A * 30:01D77N was able to bind MTB (Figures 5C,D). We found the melting temperature (T m ) of HLA-A * 30:01D77N/MTB to be 42.6 • C. In contrast, even though MTB could still be presented by HLA-A * 30:03N77D, the binding capacity decreased significantly after mutagenesis (Figure 5C). Similarly, peptide NP44 could be presented by wild type HLA-A * 30:03, but not by HLA-A * 30:01 (Figures 5E,F). Mutant HLA-A * 30:03N77D lost the ability to bind with NP44, whereas HLA-A * 30:01D77N bound NP44 with high capacity (Figures 5E,F). The peptide-binding ability of the F pocket of HLA-A * 30:01 and HLA-A * 30:03 shifted in opposite directions after mutation of residue 77. These results indicate that residue 77 is the key position involved in determining the different binding motifs between HLA-A * 30:01 and HLA-A * 30:03.
To verify the role of Asp77 in the peptide presentation of MHC I from different vertebrates other than humans, the 1,271 MHC I crystal structures available in the PDB were retrieved and chicken MHC I BF2 * 14:01 (PDB code: 4CW1), feline MHC I FLA-E * 018:01 (PDB code: 5XMF), dog MHC I DLA-88 * 508:01 (PDB code: 5F1N), and rat MHC I RT1-A a (PDB code: 1ED3) prefer peptides with positive charged Lys or Arg residue at the P residue (38)(39)(40)(41). Among these MHC Is, residue 74 and residue 116 were diversified. In contrast, residues at position 77 of these four MHC class I molecules retain a conserved Asp (Figure 6A). The F pockets of BF2 * 14:01, FLA-E * 018:01, DLA-88 * 508:01, and RT1-A a are negatively charged (Figures 6B-E). It indicated that Asp77 in the F pocket of MHC I from different vertebrates may play a key role in the binding of peptides with Lys or Arg at P .

DISCUSSION
Supertype definitions provide a pivotal tool for peptide screening in vaccine development and immune intervention strategies. Currently, the classification of some HLA I alleles into defined supertypes is in debate, but structural determination will provide visualized evidence that will aid our understanding of supertype definitions. In this study, we found that HLA-A * 30:01 possesses more features of A3 supertype compared to HLA-A * 30:03, and the peptide-binding motifs of HLA-A * 30:03 belonged to the A1A3 supertype. These conclusions were made based on the crystal structure determination of four peptide/HLA complexes and the results of a series of biochemical investigations in vitro.
Our structural studies showed that residue 77 in the F pocket may be the key residue for determining the different binding motifs of A1, A1A3, and A3 supertype alleles. When we mutated the amino acid at residue 77 of HLA-A * 30:01 and HLA-A * 30:03, we found that the binding capacity changed to the opposite direction for the two HLAs. One mutation, from Asp to Asn at position 77 in HLA-A * 30:01, enabled it to bind to the A1 supertype-binding peptides MTB and NP44. This indicated that Asp at position 77 restricted the binding of the F pocket of HLA-A * 30:01 to the positively charged residues of the binding peptides. When Asp77 was mutated to Asn, the anchor residue could be expended to other hydrophobic residues (e.g., Met or Tyr) in MTB and NP44. However, even though the binding capacity decreased when Asn77 of HLA-A * 30:03 was mutated to Asp77, the mutant HLA could still present MTB. This indicated that, although residue 77 was the main factor influencing the binding motif of the F pocket, it was not the only reason for the restricted peptide presentation.
The cross-presentation of peptides from both A1 and A3 supertypes means that HLA-A * 30:03 belongs to a special supertype, A1A3. Interestingly, the peptide-binding modes of HLA-A * 30:03 possess unique features that are different from typical A1 and A3 supertype alleles. In contrast to HLA-A * 01:01, different residues at position 114 resulted in different binding motifs of HLA-A * 30:03 by influencing the charge surrounding of the F pocket. Although residue 116 can form a stable hydrogen bond with the P residue of the peptide, the binding motifs of the F pocket did not change when Asp116 was mutated to His116. In HLA-A * 01:01, Arg114 pointed to the "mouth" of the F pocket to form a strong positively charged environment, which may repel positive amino acids, such as Lys and Arg. However, in HLA-A * 30:03, Glu114 did not participate in the formation of the F pocket. The strength of the negative charge of the HLA-A * 30:03 F pocket was between that of the A3 and A1 supertype alleles. Therefore, HLA-A * 30:03 has A1A3 supertype peptide binding characteristics. In contrast to the typical A3 supertype alleles, HLA-A * 30:03 could not present MTB when the P residue was mutated to an Arg. One possible reason for this is that Arg has a stronger positive charge than Lys, while Asn77 and Glu114 gives a weaker negative charge in the F pocket of HLA-A * 30:03 than that of A3 supertype alleles. The positive charge of Arg was too strong for it to insert into the F pocket of HLA-A * 30:03. Based on these results, we can also predict the supertype of other similar HLA alleles (Supplemental Table 1).
Screening of immunogenic peptides which are presented by specific MHC I molecules is crucial for the development of vaccines for infection diseases or cancer immunotherapy and for T-cell immune response evaluation (45)(46)(47)(48)(49)(50)(51). Recently, several pre-clinical and clinical studies have shown that vaccines targeting predicted personal tumor neoantigens are feasibility, safety, and immunogenicity (45,50,(52)(53)(54)(55). Adoptive T cell therapy that specifically recognize neoantigens has mediated substantial objective clinical regressions in patients with melanoma and metastatic breast cancer (56)(57)(58). In our previous work, even one immunogenic CD8 + T-cell peptide could stimulate a strong T-cell immune response in vivo and could reduce virus shedding during challenge in mice (25). In chickens, immunogenic CD8 + T-cell peptides have been identified from the Rous sarcoma virus and infectious bursal disease virus and these peptides had immune-protective functions (59,60). Due to an unusually large PBG in the MHC class I molecule, BF2 * 21:01, compared with BF2 * 04:01, BF2 * 21:01 is able to present a greater diversity of peptides than BF2 * 04:01. Therefore, chickens with the BF2 * 21:01 allele possess stronger antiviral abilities than those with the BF2 * 04:01 allele (59,60). However, to rapidly and precisely identify mutated epitope targets in individual patients still remains a daunting technical challenge. This indicates that binding motif-based HLA supertype classification could offers a simply and precisely way to characterize the peptides presented by a certain individual HLA allele and to understanding the disease susceptibility from the view of immunity. However, HLA alleles with single amino acid difference outside the pockets may not influence the binding motifs, but can also impact the disease status of patients by disturbing the TCR recognition (25,61).
Cross-reactive CD8 + T cells broadly exist among the population and play a pivotal role in the defense against viral infections. A number of cross-presented T-cell epitopes have been identified thus far (32,(62)(63)(64). Most of these are cross-recognized by the same HLA supertype because they have similar binding motifs. We previously reported that the HIV peptide, RT313, can be cross-recognized by HLA-A * 03:01, HLA-A * 68:01, and HLA-A * 11:01. Together with the current FIGURE 7 | Binding motifs of F pockets of HLA-A*30:01 and HLA-A*30:03. Binding motifs of the F pocket of HLA-A*30:01 (A) and HLA-A*30:03 (B) as predicted by NetMHCpan (http://www.cbs.dtu.dk/services/NetMHCpan/). According to the prediction results, the F pocket of HLA-A*30:01 prefers residues from the A1 supertype-binding motifs (Ile, Leu, and Val), residues from A3 supertype-binding motifs (Arg and Lys), and small hydrophilic amino acids (Ala, Ser, and Thr). The F pocket of HLA-A*30:03 prefers residues from A1 supertype-binding motifs (Tyr and Phe). The real binding motifs of the F pockets of HLA-A*30:01 (C) and HLA-A*30:03 (D) were verified experimentally. HLA-A*30:01 bound to peptides with A3 supertype-binding motifs (Arg and Lys) at the P position and HLA-A*30:03 bound to peptides with A1 supertype-binding motif residues (Tyr, Met, Phe, Ile, Leu, and Val), the A3 supertype-binding motif residue Lys, and small hydrophilic amino acids (Ser and Thr) at the P position.
HLA-A * 30:01, all of these HLA-A alleles are A3 supertype alleles (13,19). At the same time, some peptides can also be cross-recognized by alleles from different HLA supertypes. We have also detected some influenza virus peptides that can be presented by both HLA-A11 and HLA-A24, which belong to different supertypes, A3 and A24, respectively (65). Herein, we found that the HIV peptide, RT313, could also be presented by A3 supertype allele HLA-A * 30:01 and A1A3 supertype allele HLA-A * 30:03. We also found that NP44, which was an A1 supertype allele, HLA-A * 01:01-restricted peptide, could also be presented by HLA-A * 30:03, but not by HLA-A * 30:01 (17). This indicated that HLA-A * 30:03 could crossrecognize peptides presented by A1A3 supertype alleles, but HLA-A * 30:01 could only cross-recognize peptides presented by A3 supertype alleles. Previous work using recombinant MHC class I molecules, peptide MTB (QIMYNYPAM) has been shown to be presented by HLA-A * 30:01 (18). Here, our results indicate that MTB bind to HLA-A * 30:03, but not to HLA-A * 30:01. The difference may be due to the different expression system in the studies.
In conclusion, we characterized the different peptide presentation features of two important HLA alleles, HLA-A * 30:01 and HLA-A * 30:03. Our results provide a better understanding of the molecular immunological characteristics of A1, A1A3, and A3 supertype molecules and also provide a beneficial reference for the screening of specific T-cell recognition peptides of viruses and tumors for the vaccine development or other immune interventions.